These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 15744746)

  • 1. Use of tamoxifen in advanced-stage hepatocellular carcinoma. A systematic review.
    Nowak AK; Stockler MR; Chow PK; Findlay M
    Cancer; 2005 Apr; 103(7):1408-14. PubMed ID: 15744746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tamoxifen for hepatocellular carcinoma.
    Nowak A; Findlay M; Culjak G; Stockler M
    Cochrane Database Syst Rev; 2004; (3):CD001024. PubMed ID: 15266436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma.
    Barbare JC; Bouché O; Bonnetain F; Raoul JL; Rougier P; Abergel A; Boige V; Denis B; Blanchi A; Pariente A; Milan C; Bedenne L
    J Clin Oncol; 2005 Jul; 23(19):4338-46. PubMed ID: 15994145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tamoxifen does not improve overall survival in people with advanced-stage hepatocellular carcinoma.
    Chow PK
    Cancer Treat Rev; 2005 Oct; 31(6):491-5. PubMed ID: 16214294
    [No Abstract]   [Full Text] [Related]  

  • 5. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial.
    Chow PK; Tai BC; Tan CK; Machin D; Win KM; Johnson PJ; Soo KC;
    Hepatology; 2002 Nov; 36(5):1221-6. PubMed ID: 12395333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: a prospective randomized study.
    Liu CL; Fan ST; Ng IO; Lo CM; Poon RT; Wong J
    Am J Gastroenterol; 2000 Jan; 95(1):218-22. PubMed ID: 10638587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma.
    Schoppmeyer K; Weis S; Mössner J; Fleig WE
    Cochrane Database Syst Rev; 2009 Jul; (3):CD006745. PubMed ID: 19588401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tamoxifen does not improve survival of patients with advanced hepatocellular carcinoma.
    Riestra S; Rodriguez M; Delgado M; Suárez A; González N; de la Mata M; Diaz G; Miño-Fugarolas G; Rodrigo L
    J Clin Gastroenterol; 1998 Apr; 26(3):200-3. PubMed ID: 9600369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tamoxifen compared to best supportive care in advanced hepatocelluar carcinoma: A retrospective matched-cohort study.
    Zeeneldin AA; Eid SM; Darweesh AD; Moneer MM; Saadeldin M
    J Egypt Natl Canc Inst; 2014 Mar; 26(1):1-7. PubMed ID: 24565676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemical modulation of doxorubicin by high-dose tamoxifen in the treatment of advanced hepatocellular carcinoma.
    Cheng AL; Yeh KH; Fine RL; Chuang SE; Yang CH; Wang LH; Chen DS
    Hepatogastroenterology; 1998; 45(24):1955-60. PubMed ID: 9951847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial. CLIP Group (Cancer of the Liver Italian Programme).
    Lancet; 1998 Jul; 352(9121):17-20. PubMed ID: 9800740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is human hepatocellular carcinoma a hormone-responsive tumor?
    Di Maio M; Daniele B; Pignata S; Gallo C; De Maio E; Morabito A; Piccirillo MC; Perrone F
    World J Gastroenterol; 2008 Mar; 14(11):1682-9. PubMed ID: 18350599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hormonal treatment of human hepatocellular carcinoma.
    Di Maio M; De Maio E; Morabito A; D'Aniello R; De Feo G; Gallo C; Perrone F
    Ann N Y Acad Sci; 2006 Nov; 1089():252-61. PubMed ID: 17261772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of tamoxifen in hepatocellular carcinoma: a review and paradigm shift.
    Tan CK; Chow PK; Findlay M; Wong C; Machin D
    J Gastroenterol Hepatol; 2000 Jul; 15(7):725-9. PubMed ID: 10937676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tamoxifen in hepatocellular carcinoma.
    Chow P; Kiat TC; Choo TB; Machin D
    Lancet; 1998 Sep; 352(9130):819-20. PubMed ID: 9737316
    [No Abstract]   [Full Text] [Related]  

  • 16. Randomized controlled trial of tamoxifen versus placebo in inoperable hepatocellular carcinoma.
    Elba S; Giannuzzi V; Misciagna G; Manghisi OG
    Ital J Gastroenterol; 1994 Mar; 26(2):66-8. PubMed ID: 8032079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Octreotide therapy for hepatocellular carcinoma: a systematic review of the evidence from randomized controlled trials.
    Jia WD; Zhang CH; Xu GL; Ge YS; Wang W
    Hepatogastroenterology; 2010; 57(98):292-9. PubMed ID: 20583430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Systemic treatment for hepatocellular carcinoma].
    Spangenberg HC; Zuber-Jerger I; Thimme R; Blum HE; Von Weizsäcker F
    Zentralbl Chir; 2003 Nov; 128(11):906-10. PubMed ID: 14669110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-selective beta-blockers may reduce risk of hepatocellular carcinoma: a meta-analysis of randomized trials.
    Thiele M; Albillos A; Abazi R; Wiest R; Gluud LL; Krag A
    Liver Int; 2015 Aug; 35(8):2009-16. PubMed ID: 25581713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hepatocellular carcinoma (HCC): the long-term response to tamoxifen. A clinical case report and review of the literature].
    Recchia F; Passalacqua G; Rodorigo C; Belli L; Morgante A; Rabitti G
    Minerva Med; 1989 Dec; 80(12):1363-6. PubMed ID: 2560153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.